Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Cronos Group Inc (CRON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Cronos Group Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.68 (market cap $29.60B), while Cronos Group Inc trades at $3.13 (market cap $1.14B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 26× Cronos Group Inc's market cap, and Cronos Group Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | CRON | |
|---|---|---|
Market Cap | $29.60B | $1.14B |
Sector | Health | Health |
52-Week High | $491.22 | $3.27 |
52-Week Low | $205.48 | $2.30 |
Enterprise Value | $27.56B | $341.13M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
Cronos Group (CRON) trades at $3.125, up 4.17% today. The stock shows a bullish technical signal with strong moving average support. Recent Q2 2026 earnings beat expectations with $0.09 EPS versus $0.01 expected, driven by 58% YoY revenue growth. However, the company posted a net loss of $9.45M in 2025, though margins are improving from prior years.
Outlook is mixed; strong international expansion and product launches support growth, but negative cash flow and intense competition pose risks. Analyst consensus is cautious with 60% hold ratings. The stock offers growth potential but requires monitoring of profitability and cash management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →
